Researchers in George Mason University's Center for Infectious Disease Research (CIDR) and Tulane National Primate Research Center have conducted a breakthrough proof-of-concept study, published in ...
In the study published in the journal Emerging Microbes and Infections, the team demonstrated that the patented therapeutic candidate, an HIV-virus-like-particle (HLP), is 100 times more effective ...
The CDC's Advisory Committee on Immunization Practices (ACIP) unanimously recommended that U.S. travelers ages 12 years and older receive the virus-like particle chikungunya vaccine (Vimkunya) when ...
In a recent study published in the journal Nature Biotechnology, researchers engineered prime editor (PE)-engineered virus-like particles (eVLPs) delivering PE proteins, PE guide ribonucleic acids ...
Researchers developed a DNA-scaffolded vaccine that achieves the first step in generating a significant population of B cells that produce broadly neutralizing antibodies against HIV.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results